ANI Pharmaceuticals, Inc.
DE ˙ DB ˙ US00182C1036
54,50 € 0,00 (0,00%)
2023-08-21
AKTIENPREIS
SecurityDE:BSFA / ANI Pharmaceuticals, Inc.
InstitutionLsv Asset Management
Latest Disclosed Ownership15,500 shares
Latest Disclosed Value $ 1,192
Lsv Asset Management reports 76.14% increase in ownership of BSFA / ANI Pharmaceuticals, Inc.

On May 11, 2026 - Lsv Asset Management filed a 13F-HR form disclosing ownership of 15,500 shares of ANI Pharmaceuticals, Inc. (DE:BSFA) valued at $1,192 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 6, 2026 disclosing 8,800 shares of ANI Pharmaceuticals, Inc.. The current value of the position is $844,750 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-11 2026-03-31 13F ANI Pharmaceuticals COM 00182C103 15,500 6,700 76.14 1 0.0026
2026-02-06 2025-12-31 13F ANI Pharmaceuticals COM 00182C103 8,800 8,800 1 0.0015
2023-02-08 2022-12-31 13F ANI Pharmaceuticals COM 00182C103 0 -35,300 -100.00 0 -100.00
2022-11-07 2022-09-30 13F/A-1 ANI Pharmaceuticals COM 00182C103 35,300 -28,700 -44.84 1,135 -40.23 0.0027
2022-11-04 2022-09-30 13F ANI Pharmaceuticals COM 00182C103 64,000 0 1,899 0.0041
2022-08-10 2022-06-30 13F ANI Pharmaceuticals COM 00182C103 64,000 -2,600 -3.90 1,899 1.44 0.0041
2022-05-12 2022-03-31 13F ANI Pharmaceuticals COM 00182C103 66,600 3,300 5.21 1,872 -35.82 0.0034
2022-01-28 2021-12-31 13F ANI Pharmaceuticals COM 00182C103 63,300 -25,400 -28.64 2,917 0.21 0.0052
2021-11-04 2021-09-30 13F ANI Pharmaceuticals COM 00182C103 88,700 0 0.00 2,911 -6.34 0.0053
2021-08-04 2021-06-30 13F ANI Pharmaceuticals COM 00182C103 88,700 2,514 2.92 3,108 -0.19 0.0053
2021-04-30 2021-03-31 13F ANI Pharmaceuticals COM 00182C103 86,186 20,886 31.98 3,114 64.24 0.0053
2021-02-08 2020-12-31 13F ANI Pharmaceuticals COM 00182C103 65,300 -900 -1.36 1,896 1.55 0.0034
2020-10-23 2020-09-30 13F ANI Pharmaceuticals COM 00182C103 66,200 -3,200 -4.61 1,867 -16.80 0.0038
2020-08-05 2020-06-30 13F ANI Pharmaceuticals COM 00182C103 69,400 -2,100 -2.94 2,244 -22.94 0.0047
2020-05-07 2020-03-31 13F ANI Pharmaceuticals COM 00182C103 71,500 -400 -0.56 2,912 -34.33 0.0070
2020-02-10 2019-12-31 13F ANI Pharmaceuticals COM 00182C103 71,900 -23,300 -24.47 4,434 -36.09 0.0069
2019-11-07 2019-09-30 13F ANI Pharmaceuticals COM 00182C103 95,200 -18,800 -16.49 6,938 -25.96 0.0115
2019-08-08 2019-06-30 13F/A-1 ANI Pharmaceuticals COM 00182C103 114,000 32,215 39.39 9,370 62.42 0.0151
2019-08-07 2019-06-30 13F ANI Pharmaceuticals COM 00182C103 81,785 0 5,769
2019-05-07 2019-03-31 13F ANI Pharmaceuticals COM 00182C103 81,785 17,885 27.99 5,769 100.59 0.0092
2019-02-05 2018-12-31 13F ANI Pharmaceuticals COM 00182C103 63,900 -231,000 -78.33 2,876 -82.75 0.0051
2018-11-06 2018-09-30 13F ANI Pharmaceuticals COM 00182C103 294,900 -5,500 -1.83 16,673 -16.91 0.0249
2018-08-08 2018-06-30 13F ANI Pharmaceuticals COM 00182C103 300,400 -5,400 -1.77 20,066 12.71 0.0314
2018-05-04 2018-03-31 13F ANI Pharmaceuticals COM 00182C103 305,800 280,600 1,113.49 17,803 996.24 0.0283
2018-01-31 2017-12-31 13F ANI Pharmaceuticals COM 00182C103 25,200 900 3.70 1,624 27.37 0.0026
2017-11-13 2017-09-30 13F ANI Pharmaceuticals COM 00182C103 24,300 0 0.00 1,275 12.14 0.0021
2017-08-09 2017-06-30 13F ANI Pharmaceuticals COM 00182C103 24,300 0 0.00 1,137 -5.49 0.0020
2017-05-01 2017-03-31 13F ANI Pharmaceuticals COM 00182C103 24,300 -1,900 -7.25 1,203 -24.24 0.0022
2017-02-07 2016-12-31 13F ANI Pharmaceuticals COM 00182C103 26,200 10,300 64.78 1,588 50.66 0.0029
2016-11-07 2016-09-30 13F ANI PHARMACEUTICALS COM 00182C103 15,900 0 0.00 1,054 18.83 0.0021
2016-08-05 2016-06-30 13F ANI PHARMACEUTICALS COM 00182C103 15,900 -300 -1.85 887 62.75 0.0018
2016-05-10 2016-03-31 13F ANI PHARMACEUTICALS COM 00182C103 16,200 -600 -3.57 545 -28.10 0.0011
2016-02-03 2015-12-31 13F Ani Pharmaceuticals COM 00182C103 16,800 6,600 64.71 758 88.09 0.0016
2015-11-05 2015-09-30 13F Ani Pharmaceuticals COM 00182C103 10,200 0 0.00 403 -36.23 0.0009
2015-08-07 2015-06-30 13F Ani Pharmaceuticals COM 00182C103 10,200 10,200 632 0.0013
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.